1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Pen Needles Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of diabetes with increasing awareness about diabetes management
5.1.1.2. Growing trend towards self-administration of medication at home
5.1.1.3. Increasing availability of pen needles through online pharmacy
5.1.2. Restraints
5.1.2.1. Product recall impacting brand reputation
5.1.3. Opportunities
5.1.3.1. Continuous innovations in the development of pen needles
5.1.3.2. High potential of pen needles for skin and hair treatment
5.1.4. Challenges
5.1.4.1. Risk of contamination and infection associated with pen needles
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing use of safety pen needles for minimization of needlestick injuries amongst patients
5.2.2. Length: Increasing advancements in manufacturing techniques to improve performance at smaller needle lengths
5.2.3. Mode of Purchase: Development of innovative products to extend access to specialized prescription devices
5.2.4. Sales Channel: Online sales channel gaining traction with its competitive pricing structure and broader product offerings
5.2.5. Application: Rising utilization of pen needles for minimally invasive skin procedures
5.2.6. End-Use: Employment of single-use disposable pen needles across homecare settings
5.3. Market Trend Analysis
5.3.1. Growing availability of better reimbursement policies for pen needles and insulin drugs & devices in the Americas
5.3.2. Increasing awareness about diabetes and significant improvement in healthcare infrastructure in the Asia-Pacific
5.3.3. Expanding government support for diabetes prevention coupled with strong foothold of pharmaceutical companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Pen Needles Market, by Product
6.1. Introduction
6.2. Safety Pen Needles
6.3. Standard Pen Needles
7. Pen Needles Market, by Length
7.1. Introduction
7.2. 10mm
7.3. 12mm
7.4. 4mm
7.5. 5mm
7.6. 6mm
7.7. 8mm
8. Pen Needles Market, by Application
8.1. Introduction
8.2. GLP-1 Therapy
8.3. Growth Hormone Therapy
8.4. Hair Treatment
8.5. Insulin Therapy
8.6. Skin Treatment
9. Pen Needles Market, by Mode of Purchase
9.1. Introduction
9.2. OTC
9.3. Prescription
10. Pen Needles Market, by Sales Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Pen Needles Market, by End-Use
11.1. Introduction
11.2. Homecare
11.3. Hospitals & Clinics
12. Americas Pen Needles Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Pen Needles Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Pen Needles Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
15.3.1. Merger & Acquisition
15.3.1.1. Novo Nordisk Enters Exclusive Negotiations to Acquire a Controlling Stake in BIOCORP, to be Followed by a Tender Offer on all Remaining Shares
15.3.1.2. Gilde Healthcare Acquires Needle Manufacturer Europin
15.3.2. New Product Launch & Enhancement
15.3.2.1. Terumo India Introduces FineGlide – Sterile Pen Needle for Patients Requiring Insulin Injections or Other Self-medications
15.3.2.2. Owen Mumford Announces Active Safety Pen Needle Join the Unifine Brand
15.3.2.3. Roche Diabetes Care Launches ACCU-FINE Pen Needles for Painless Insulin Delivery
15.3.3. Award, Recognition, & Expansion
15.3.3.1. Montmed Inc. Announces Issuance of a Second U.S. Patent for Sitesmart Pen Needles
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. AdvaCare Pharma
16.1.2. Advocate by Pharma Supply, Inc.
16.1.3. Allison Medical, Inc.
16.1.4. ARKRAY, Inc.
16.1.5. Ayset Health Services
16.1.6. B. Braun SE
16.1.7. Becton, Dickinson and Company
16.1.8. Berpu Medical Technology Co., Ltd.
16.1.9. Cardinal Health, Inc.
16.1.10. F. Hoffmann-La Roche Ltd.
16.1.11. Gan & Lee Pharmaceuticals Co., Ltd.
16.1.12. GlucoRx Ltd.
16.1.13. Hindustan Syringes & Medical Devices Ltd.
16.1.14. IME-DC GmbH
16.1.15. Jiangsu Micsafe Medical Technology Co., Ltd.
16.1.16. Jinan Babio Biotechnology Co., Ltd.
16.1.17. Lepu Medical Technology (Beijing) Co., Ltd.
16.1.18. Medexel Co., Ltd.
16.1.19. Medical Technology and Devices S.p.A.
16.1.20. MEDISEC Healthcare
16.1.21. Montméd Inc.
16.1.22. Narang Medical Limited
16.1.23. Neon Diagnostics Ltd.
16.1.24. Nipro Corporation
16.1.25. Novo Nordisk A/S
16.1.26. Owen Mumford Limited
16.1.27. Promisemed Medical Devices Inc.
16.1.28. Shanghai Berpu Medical Co., Ltd
16.1.29. Shanghai Kindly Enterprise Development Group
16.1.30. Sol-Millennium
16.1.31. Spirit Healthcare Pty Ltd.
16.1.32. Terumo Corporation
16.1.33. Trividia Health, Inc.
16.1.34. UltiMed, Inc.
16.1.35. Van Heek Medical
16.1.36. Vitrex Medical A/S
16.1.37. Vogt Medical Vertrieb GmbH
16.1.38. Ypsomed Holding AG
16.1.39. Zibo Sunrise Medical Co., Ltd.
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
